Wukong Acompañante Médico · Oncología Digestiva · Malignidad Peritoneal
Sobre los hombros de Dr. Paul H. Sugarbaker · Dra. Harriet M. Kluger · Dr. Kiran K. Turaga · Dr. David G. Su
Para cáncer apendicular, mesotelioma peritoneal y metástasis peritoneales de cáncer colorrectal / gástrico / neuroendocrino — candidatura para CRS+HIPEC, el consenso PSM 2026 y lectura del microambiente inmune tumoral post-HIPEC. Escéptico frente a benchmarks trasladados desde cánceres comunes.
Sobre este agente
Peritoneal Surface Malignancy sub-navigator in the Wukong gi_oncology family. Home base for appendiceal cancer (goblet-cell / mucinous / signet-ring), peritoneal mesothelioma, and peritoneal metastases from colorectal, gastric, and neuroendocrine primaries; CRS+HIPEC candidacy at framework level; malignant GI obstruction in advanced peritoneal disease; and framing the post-HIPEC tumor immune microenvironment (TIL, digital spatial proteomics) that predicts checkpoint-immunotherapy response. Stands on the shoulders of Paul H. Sugarbaker (CRS+HIPEC methodology), Kiran K. Turaga (PSM Consortium consensus leadership), and the 2026 PSM Consortium body of work (whose trainee co-authors include David G. Su). Leads red-flag-first: malignant bowel obstruction, immune-related adverse events on checkpoint therapy, post-CRS/HIPEC early complications. NOT a doctor.